Baron Capital, an asset management firm, recently published its Q1 2026 investor letter for the Baron Health Care Fund. The fund recorded a 6.97% decrease in institutional shares during this period, contrasting with a 4.88% dip for the Russell 3000 Health Care Index and a 3.96% fall for the broader Russell 3000 Index. This underperformance was primarily attributed to specific stock choices, yet the fund has demonstrated an annualized appreciation of 9.39% since its launch, surpassing the benchmark's 8.97% gain. Looking ahead, the fund remains optimistic about the healthcare industry's trajectory, citing an aging global demographic, increasing rates of chronic illnesses, breakthroughs in biotechnology, and a general rise in healthcare expenditures as key growth drivers.
A notable factor contributing to the fund's Q1 2026 performance was its deliberate exclusion of Amgen Inc. (NASDAQ:AMGN) from its holdings. While Amgen's shares saw an 8% increase during the quarter, closing at $329.82 on May 1, 2026, with a 17.77% gain over the preceding 52 weeks and a market capitalization of $178 billion, the Baron Health Care Fund deemed it overvalued. The fund's letter indicated that Amgen did not meet their internal investment return threshold, despite its strong performance. This decision underscores the fund's selective investment strategy, prioritizing long-term growth potential and valuation alignment over short-term gains.
Although Amgen is a significant player in the biotechnology sector, the Baron Health Care Fund's investor letter revealed that the company was not among the top 40 most favored stocks by hedge funds at the close of the fourth quarter, despite an increase in hedge fund portfolios holding Amgen. The fund's management suggests that certain artificial intelligence stocks present more attractive upside potential with reduced downside risk, aligning with their pursuit of superior investment opportunities. This strategic positioning reflects a broader investment philosophy focused on identifying undervalued assets that can generate substantial returns over time.
The Baron Health Care Fund's experience with Amgen underscores a crucial investment principle: true success lies not merely in what is owned, but also in what is thoughtfully omitted. In a dynamic market, discerning judgment and adherence to a clear investment philosophy allow for the pursuit of genuine value and sustained prosperity, guiding investors toward opportunities that promise long-term growth and stability.